Author(s): Ahrn B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R
Abstract Share this page
Abstract OBJECTIVE: To examine the efficacy and safety of lixisenatide (20 μg once daily, administered before the morning or evening meal) as add-on therapy in patients with type 2 diabetes insufficiently controlled with metformin alone. RESEARCH DESIGN AND METHODS: This was a 24-week, randomized, double-blind, placebo-controlled study in 680 patients with inadequately controlled type 2 diabetes (HbA1c 7-10\% [53-86 mmol/mol]). Patients were randomized to lixisenatide morning (n = 255), lixisenatide evening (n = 255), placebo morning (n = 85), or placebo evening (n = 85) injections. RESULTS: Lixisenatide morning injection significantly reduced mean HbA1c versus combined placebo (mean change -0.9\% [9.8 mmol/mol] vs. -0.4\% [4.4 mmol/mol]; least squares [LS] mean difference vs. placebo -0.5\% [5.5 mmol/mol], P < 0.0001). HbA1c was significantly reduced by lixisenatide evening injection (mean change -0.8\% [8.7 mmol/mol] vs. -0.4\% [4.4 mmol/mol]; LS mean difference -0.4\% [4.4 mmol/mol], P < 0.0001). Lixisenatide morning injection significantly reduced 2-h postprandial glucose versus morning placebo (mean change -5.9 vs. -1.4 mmol/L; LS mean difference -4.5 mmol/L, P < 0.0001). LS mean difference in fasting plasma glucose was significant in both morning (-0.9 mmol/L, P < 0.0001) and evening (-0.6 mmol/L, P = 0.0046) groups versus placebo. Mean body weight decreased to a similar extent in all groups. Rates of adverse events were 69.4\% in both lixisenatide groups and 60.0\% in the placebo group. Rates for nausea and vomiting were 22.7 and 9.4\% for lixisenatide morning and 21.2 and 13.3\% for lixisenatide evening versus 7.6 and 2.9\% for placebo, respectively. Symptomatic hypoglycemia occurred in 6, 13, and 1 patient for lixisenatide morning, evening, and placebo, respectively, with no severe episodes. CONCLUSIONS: In patients with type 2 diabetes inadequately controlled on metformin, lixisenatide 20 μg once daily administered in the morning or evening significantly improved glycemic control, with a pronounced postprandial effect, and was well tolerated. TRIAL REGISTRATION: ClinicalTrials.gov NCT00712673.
This article was published in Diabetes Care
and referenced in Journal of Developing Drugs